Galectin-3, renal function, and clinical outcomes: Results from the luric and 4D studies

Journal of the American Society of Nephrology

Volumn 26, Issue 9, 2015, Pages 2213-2221

  Drechsler, Christiane ^a   Delgado, Graciela ^b   Wanner, Christoph ^a   Blouin, Katja ^a   Pilz, Stefan ^c   Tomaschitz, Andreas ^c,d,e   Kleber, Marcus E ^b   Dressel, Alexander ^b   Willmes, Christoph ^a   Krane, Vera ^a   Krämer, Bernhard K ^b   März, Winfried ^b,f   Ritz, Eberhard ^g   Van Gilst, Wiek H ^h   Van Der Harst, Pim ^h   De Boer, Rudolf A ^h  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d Specialist Clinic for Rehabilitation PV Bad Aussee   (Austria)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f SYNLAB ACADEMY   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GALECTIN 3; GLYCOSYLATED HEMOGLOBIN; GALECTIN-3, HUMAN;

ADULT; ADVERSE OUTCOME; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; AGED; BLOOD; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DIABETIC NEPHROPATHIES; EPIDEMIOLOGY; GERMANY; INFECTION; MIDDLE AGED; MORTALITY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; SEVERITY OF ILLNESS INDEX;

AGED; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; GERMANY; GLOMERULAR FILTRATION RATE; HUMANS; INFECTION; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX;

EID: 84930923324     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014010093     Document Type: Article

References (36)

1. Liu FT, Hsu DK, Zuberi RI, Kuwabara I, Chi EY, Henderson WR Jr: Expression and function of galectin-3, a beta-galactoside-binding lectin, in humanmonocytes andmacrophages.AmJ Pathol 147: 1016-1028, 1995
2. Yang RY, Rabinovich GA, Liu FT: Galectins: Structure, function and therapeutic potential. Expert Rev Mol Med 10: e17, 2008
3. Kim H, Lee J, Hyun JW, Park JW, Joo HG, Shin T: Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 31: 655-662, 2007
4. Vasta GR: Galectins as pattern recognition receptors: Structure, function, and evolution. Adv Exp Med Biol 946: 21-36, 2012
5. de Boer RA, Voors AA,Muntendam P, vanGilstWH, van Veldhuisen DJ: Galectin-3: A novel mediator of heart failure development and progression. Eur J Heart Fail 11: 811-817, 2009
6. Liu FT, Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer 5: 29-41, 2005
7. Rabinovich GA, Liu FT, HirashimaM, Anderson A: An emerging role for galectins in tuning the immune response: Lessons from experimental models of inflammatory disease, autoimmunity and cancer. Scand J Immunol 66: 143-158, 2007
8. Iacobini C,Amadio L,Oddi G, Ricci C, Barsotti P,Missori S, SorciniM,Di Mario U, Pricci F, Pugliese G: Role of galectin-3 in diabetic nephropathy. J Am Soc Nephrol 14[Suppl 3]: S264-S270, 2003
9. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T: Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172: 288-298, 2008
10. Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA: Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS ONE 6: e18683, 2011
11. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ: Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43: 60-68, 2011
12. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ: Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: Data from the DEAL-HF study. Clin Res Cardiol 99: 323-328, 2010
13. O'Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS: Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol 24: 1470-1477, 2013
14. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJ, van der Harst P: The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 272: 55-64, 2012
15. Gopal DM, Kommineni M, Ayalon N, Koelbl C, Ayalon R, Biolo A, Dember LM, Downing J, Siwik DA, Liang CS, ColucciWS: Relationship of plasma galectin-3 to renal function in patients with heart failure: Effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc 1: e000760, 2012
16. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL: Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 108: 385-390, 2011
17. Bullock SL, Johnson TM, Bao Q, Hughes RC, Winyard PJ, Woolf AS: Galectin-3 modulates ureteric bud branching in organ culture of the developing mouse kidney. J Am Soc Nephrol 12: 515-523, 2001
18. Winyard PJ, Bao Q, Hughes RC, Woolf AS: Epithelial galectin-3 during human nephrogenesis and childhood cystic diseases. J Am Soc Nephrol 8: 1647-1657, 1997
19. Okamura DM, Pasichnyk K, Lopez-Guisa JM, Collins S, Hsu DK, Liu FT, Eddy AA: Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am J Physiol Renal Physiol 300: F245-F253, 2011
20. Nishiyama J, Kobayashi S, Ishida A, Nakabayashi I, Tajima O, Miura S, Katayama M, Nogami H: Up-regulation of galectin-3 in acute renal failure of the rat. Am J Pathol 157: 815-823, 2000
21. von Mach T, Carlsson MC, Straube T, Nilsson U, Leffler H, Jacob R: Ligand binding and complex formation of galectin-3 is modulated by pH variations. Biochem J 457: 107-115, 2014
22. Shamseddin MK, Parfrey PS: Sudden cardiac death in chronic kidney disease: Epidemiology and prevention. Nat Rev Nephrol 7: 145-154, 2011
23. Nachtigal M, Al-Assaad Z, Mayer EP, Kim K, Monsigny M: Galectin-3 expression in human atherosclerotic lesions. Am J Pathol 152: 1199-1208, 1998
24. Iacobini C,Menini S, Ricci C, Scipioni A, Sansoni V, Cordone S, Taurino M, Serino M, Marano G, Federici M, Pricci F, Pugliese G: Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: Role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol 29: 831-836, 2009
25. Nachtigal M, Ghaffar A,Mayer EP:Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 172: 247-255, 2008
26. Jeon SB, Yoon HJ, Chang CY, Koh HS, Jeon SH, Park EJ: Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. J Immunol 185: 7037-7046, 2010
27. Sasaki S, Bao Q, Hughes RC: Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J Pathol 187: 481-489, 1999
28. Ho JE, Liu C, Lyass A, Courchesne P, PencinaMJ, Vasan RS, LarsonMG, Levy D: Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60: 1249-1256, 2012
29. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM: Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J AmColl Cardiol 48: 1217-1224, 2006
30. WannerC, Krane V,MrzW,Olschewski M, AsmusHG, KrmerW, Kühn KW, Kütemeyer H, Mann JF, Ruf G, Ritz E; Deutsche Diabetes-Dialyse-Studie (4D) Study Group: Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): Demographic and baseline characteristics. Kidney Blood Press Res 27: 259-266, 2004
31. Wanner C, Krane V, Mrz W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
32. Winkelmann BR, Mrz W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J; LURIC Study Group (LUdwigshafen RIsk and Cardiovascular Health): Rationale and design of the LURIC study-a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2[Suppl 1]: S1-S73, 2001
33. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS; CKD-EPI Investigators: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367: 20-29, 2012
34. National Kidney Foundation: KDIGO 2012 Clinical Practice Guideline for the Evaluation andManagement of Chronic Kidney Disease. Kidney Int Suppl 3: 1-150, 2013
35. Christenson RH, Duh SH,Wu AH, Smith A, Abel G, deFilippi CR,Wang S, Adourian A, Adiletto C, Gardiner P: Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. Clin Biochem 43: 683-690, 2010
36. La'ulu SL, Apple FS, Murakami MM, Ler R, Roberts WL, Straseski JA: Performance characteristics of the ARCHITECT Galectin-3 assay. Clin Biochem 46: 119-122, 2013